GlassScriptPhysician profile
Anthony M Boulos
NPI 1649402751
$23,573.79
in general payments reported to CMS, 2019-2025
32 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $5,240 · 2021: $2,362 · 2022: $1,943 · 2023: $1,111 · 2024: $2,030 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,290 · Education: $49.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,113.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,290.00 |
| Education | $49.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $12,830.92 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $4,310.77 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $2,569.76 | 2019-2023 | |
| Veran Medical Technologies, INC. | $482.54 | 2019-2020 | |
| Glaxosmithkline, LLC. | $395.68 | 2019-2025 | Nucala |
| United Therapeutics Corporation | $382.52 | 2021-2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.16 | 2019-2023 | Ofev |
| Actelion Pharmaceuticals US, INC. | $264.62 | 2019-2025 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $230.68 | 2020-2024 | Acthar |
| Regeneron Healthcare Solutions, INC. | $228.70 | 2019-2023 | Dupixent |
| Pulmonx Corporation | $225.34 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Noah Medical Corporation | $196.79 | 2023-2025 | Galaxy |
| Jazz Pharmaceuticals INC. | $127.69 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $126.66 | 2020-2024 | Dificid, Zerbaxa, Recarbrio |
| Amgen INC. | $116.81 | 2022-2024 | Tezspire |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $113.72 | 2022 | |
| Inspire Medical Systems, INC. | $111.69 | 2019 | |
| Harmony Biosciences LLC | $80.23 | 2021-2023 | Wakix |
| Mylan Specialty L.P. | $68.44 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $66.17 | 2020-2024 | Glassia, Hyqvia |
| Novartis Pharmaceuticals Corporation | $64.84 | 2019-2023 | |
| Csl Behring | $45.97 | 2022-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $28.67 | 2023 | |
| Genentech USA, INC. | $27.63 | 2022-2023 | Xolair |
| Philips North America LLC | $25.30 | 2024 | (Ak6) Vest Therapy |
| Pfizer INC. | $23.03 | 2020 | |
| Electromed, INC. | $22.33 | 2023 | Smartvest |
| Mallinckrodt Enterprises LLC | $15.08 | 2019 | |
| Baxter Healthcare | $14.65 | 2023 | Hillrom - Life 2000 Ventilation System |
| Insmed, INC. | $13.04 | 2020 | |
| Itamar Medical INC | $10.82 | 2023 | Watchpatone |
| Grifols Shared Services North America, INC. | $3.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Boulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.